Vivasure Medical Names Andrew Glass as CEO

April 6, 2021—Vivasure Medical, which is focused on fully absorbable solutions for large-bore percutaneous vessel closure, announced that Andrew Glass has assumed the role of Chief Executive Officer (CEO). The company’s founder and former CEO, Ger Brett, will transition to serving as Chief Operating Officer.

Based in Galway, Ireland, Vivasure develops advanced polymer implants and delivery systems, primarily for vessel closure in cardiology, interventional radiology, and vascular surgery. Vivasure’s PerQseal device for large-bore arterial closure is currently available in Europe.

According to the company, Mr. Glass has extensive leadership, commercial operations, and product development experience in the medical technology and cardiovascular fields. He held senior leadership roles at Abbott Laboratories for the past 15 years, most recently as Regional Director at Abbott Vascular, where he was responsible for commercial operations for 13 European countries. Previously, he served in senior leadership positions in general management, business development, and marketing in Europe, Asia-Pacific, and the United States.

Mr. Glass has a proven track record of aligning research and development efforts with commercial goals to drive the profitable and predictable growth of innovative technologies in the cardiovascular space, stated Vivasure.

“I’m excited to be joining Vivasure during this momentous time of growth and development,” commented Mr. Glass in the announcement. “The company possesses a revolutionary technology to ensure success for the ever-increasing volume of percutaneous cardiovascular procedures performed every year around the world. I look forward to continuing to build on the tremendous progress Vivasure has made with its clinical and commercial programs under Ger’s exceptional leadership.”

Mr. Brett added, “We’re thrilled to welcome an executive of Andrew’s caliber to the Vivasure team. He’s an experienced and forward-thinking leader with a drive for growth. I look forward to working closely with him to continue making strides towards our mission to pioneer a new class of technology for percutaneous vessel closure.”